Axios @axios
Biogen executives used their earnings day to take aim at critics and the media, saying the federal approval of the company's unproven Alzheimer's drug "has been the subject of extensive misinformation and misunderstanding." https://t.co/AlPskxqj6p — PolitiTweet.org